Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma.
fibroblast growth factor 9
hepatocellular carcinoma
malignant phenotype
tumour progression
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
05
12
2019
revised:
15
04
2020
accepted:
01
05
2020
pubmed:
8
5
2020
medline:
22
6
2021
entrez:
8
5
2020
Statut:
ppublish
Résumé
Recently, overexpression of the fibroblast growth factor receptor 3 (FGFR3) splice variants FGFR3-IIIb and FGFR3-IIIc was found in ~50% of hepatocellular carcinoma (HCC). Here, we aim to identify FGFR3-IIIb/IIIc ligands, which drive the progression of HCC. FACS, MTT assay and/or growth curves served to identify the FGFR3-IIIb/IIIc ligand being most effective to induce growth of hepatoma/hepatocarcinoma cell lines, established from human HCC. The most potent FGF was characterized regarding the expression levels in epithelial and stromal cells of liver and HCC and impact on neoangiogenesis, clonogenicity and invasive growth of hepatoma/hepatocarcinoma cells. Among all FGFR3-IIIb/IIIc ligands tested, FGF9 was the most potent growth factor for hepatoma/hepatocarcinoma cells. Replication and/or sprouting of blood/lymphendothelial cells was stimulated as well. FGF9 occurred mainly in stromal cells of unaltered liver but in epithelial cells of HCC. Every fifth HCC exhibited overexpressed FGF9 and frequent co-upregulation of FGFR3-IIIb/IIIc. In hepatoma/hepatocarcinoma cells FGF9 enhanced the capability for clonogenicity and disintegration of the blood and lymphatic endothelium, being most pronounced in cells overexpressing FGFR3-IIIb or FGFR3-IIIc, respectively. Any of the FGF9 effects in hepatoma/hepatocarcinoma cells was blocked completely by applying the FGFR1-3-specific tyrosine kinase inhibitor BGJ398 or siFGFR3, while siFGFR1/2/4 were mostly ineffective. FGF9 acts via FGFR3-IIIb/IIIc to enhance growth and aggressiveness of HCC cells. Accordingly, blockade of the FGF9-FGFR3-IIIb/IIIc axis may be an efficient therapeutic option for HCC patients.
Sections du résumé
BACKGROUND & AIMS
Recently, overexpression of the fibroblast growth factor receptor 3 (FGFR3) splice variants FGFR3-IIIb and FGFR3-IIIc was found in ~50% of hepatocellular carcinoma (HCC). Here, we aim to identify FGFR3-IIIb/IIIc ligands, which drive the progression of HCC.
METHODS
FACS, MTT assay and/or growth curves served to identify the FGFR3-IIIb/IIIc ligand being most effective to induce growth of hepatoma/hepatocarcinoma cell lines, established from human HCC. The most potent FGF was characterized regarding the expression levels in epithelial and stromal cells of liver and HCC and impact on neoangiogenesis, clonogenicity and invasive growth of hepatoma/hepatocarcinoma cells.
RESULTS
Among all FGFR3-IIIb/IIIc ligands tested, FGF9 was the most potent growth factor for hepatoma/hepatocarcinoma cells. Replication and/or sprouting of blood/lymphendothelial cells was stimulated as well. FGF9 occurred mainly in stromal cells of unaltered liver but in epithelial cells of HCC. Every fifth HCC exhibited overexpressed FGF9 and frequent co-upregulation of FGFR3-IIIb/IIIc. In hepatoma/hepatocarcinoma cells FGF9 enhanced the capability for clonogenicity and disintegration of the blood and lymphatic endothelium, being most pronounced in cells overexpressing FGFR3-IIIb or FGFR3-IIIc, respectively. Any of the FGF9 effects in hepatoma/hepatocarcinoma cells was blocked completely by applying the FGFR1-3-specific tyrosine kinase inhibitor BGJ398 or siFGFR3, while siFGFR1/2/4 were mostly ineffective.
CONCLUSIONS
FGF9 acts via FGFR3-IIIb/IIIc to enhance growth and aggressiveness of HCC cells. Accordingly, blockade of the FGF9-FGFR3-IIIb/IIIc axis may be an efficient therapeutic option for HCC patients.
Identifiants
pubmed: 32378800
doi: 10.1111/liv.14505
pmc: PMC7496895
doi:
Substances chimiques
FGF9 protein, human
0
Fibroblast Growth Factor 9
0
FGFR3 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 3
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2279-2290Subventions
Organisme : Austrian Science Fund FWF
ID : P 30105
Pays : Austria
Informations de copyright
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
J Biol Chem. 2006 Jun 9;281(23):15694-700
pubmed: 16597617
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
Hepatology. 2013 Jul;58(1):205-17
pubmed: 23401231
BMC Cancer. 2015 Apr 30;15:333
pubmed: 25925261
J Med Chem. 2011 Oct 27;54(20):7066-83
pubmed: 21936542
Carcinogenesis. 2014 Oct;35(10):2331-8
pubmed: 25031272
Oncotarget. 2016 Jun 14;7(24):36655-36665
pubmed: 27166269
Cancer Res. 2016 Jul 15;76(14):4205-15
pubmed: 27267910
Cancer Treat Rev. 2018 Jul;68:16-24
pubmed: 29783126
PLoS One. 2013 Aug 28;8(8):e72662
pubmed: 24015269
Biomed Res Int. 2016;2016:8323747
pubmed: 27699175
J Hepatol. 2017 Aug;67(2):302-309
pubmed: 28336466
Arch Toxicol. 2018 Feb;92(2):953-966
pubmed: 29270806
J Hepatocell Carcinoma. 2014 May 29;1:43-54
pubmed: 27508175
J Biol Chem. 2001 Feb 9;276(6):4322-9
pubmed: 11060292
Hepatology. 2015 Dec;62(6):1767-78
pubmed: 26235436
Nucleic Acids Res. 2014 Mar;42(5):2932-44
pubmed: 24334956
Nat Biotechnol. 2011 May;29(5):421-7
pubmed: 21499246
Dig Dis Sci. 2017 Feb;62(2):407-417
pubmed: 28058595
Semin Cell Dev Biol. 2016 May;53:126-35
pubmed: 26463732
Hepatology. 2011 Mar;53(3):854-64
pubmed: 21319186
Liver Int. 2020 Sep;40(9):2279-2290
pubmed: 32378800
Nat Genet. 2009 Mar;41(3):289-98
pubmed: 19219044
Cancer Treat Rev. 2016 May;46:51-62
pubmed: 27109926
Oncol Rep. 2017 Oct;38(4):1977-1984
pubmed: 28849071
Br J Cancer. 2008 Jul 8;99(1):151-9
pubmed: 18594539
Structure. 2017 Sep 5;25(9):1325-1336.e3
pubmed: 28757146
Mol Biol Rep. 2016 May;43(5):427-36
pubmed: 27022737